United Therapeutics (UTHR) Cash & Equivalents Growth (1y) (2010 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Cash & Equivalents Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.04 Bn | 624.28 Bn | 17.26 Bn | 9.93% |
| 2 | AbbVie | 440.25 Bn | 433.68 Bn | 12.70 Bn | 1.58% |
| 3 | Merck | 365.65 Bn | 358.51 Bn | 12.21 Bn | -14.46% |
| 4 | Novartis Ag | 266.64 Bn | 258.95 Bn | 11.24 Bn | 14.42% |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | -40.42% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -57.55% |
| 7 | Revolution Medicines | 44.19 Bn | 44.19 Bn | - | - |
| 8 | Incyte | 25.29 Bn | 20.75 Bn | 1.57 Bn | 103.71% |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 13.19% |
| 10 | Neurocrine Biosciences | 15.52 Bn | 15.13 Bn | 935.80 Mn | 25.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.19% |
| Mar 31, 2026 | -32.64% |
| Dec 31, 2025 | -8.25% |
| Sep 30, 2025 | -13.76% |
| Jun 30, 2025 | 17.51% |
| Mar 31, 2025 | 51.81% |
| Dec 31, 2024 | 40.53% |
| Sep 30, 2024 | 40.28% |
| Jun 30, 2024 | 27.02% |
| Mar 31, 2024 | 7.56% |
| Dec 31, 2023 | 25.65% |
| Sep 30, 2023 | 14.57% |
| Jun 30, 2023 | 34.22% |
| Mar 31, 2023 | 43.06% |
| Dec 31, 2022 | 7.42% |
| Sep 30, 2022 | 6.42% |
| Jun 30, 2022 | -15.60% |
| Mar 31, 2022 | -2.28% |
| Dec 31, 2021 | 21.13% |
| Sep 30, 2021 | 35.56% |